ZIOP earnings call for the period ending December 31, 2018.
News & Analysis: ZIOPHARM Oncology
Can these fast-rising biotech stocks keep the momentum going?
The company's second-quarter update is fueling optimism.
A game of musical chairs on its board of directors causes investors to sing a new tune about this beaten-down biotech.
Ziopharm has been stung by a series of clinical setbacks this year, and the company is now facing a serious cash crunch to boot.
Which beaten-down biotech stock wins in a head-to-head match-up?
A disappointing setback in a key clinical trial has investors scurrying for the exit.
This clinical-stage biotech has a promising pipeline. But is that promise enough?
Ziopharm's stock finally showed some signs of life last month, but this rally might be short-lived.
Ziopharm Oncology's stock has failed to find a bottom this year. Is a turnaround finally close at hand?